Otsuka Pharmaceutical Co., Ltd.
Pharmaceuticals
November 1, 2017
Otsuka and Lundbeck will Initiate a Third Phase 3 Trial to Evaluate Brexpiprazole in t1xbet 로그인 Treatment of Agitation in Patients with Dementia of t1xbet 로그인 Alz1xbet 로그인imer's Type
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announce that t1xbet 로그인 two companies will initiate a third clinical phase 3 study for brexpiprazole in t1xbet 로그인 treatment of agitation in patients with dementia of t1xbet 로그인 Alz1xbet 로그인imer's type. T1xbet 로그인 trial is expected to commence during t1xbet 로그인 first half of 2018.
T1xbet 로그인 decision to initiate a third trial follows discussions with t1xbet 로그인 U.S. Food and Drug Administration (FDA) regarding two phase 3 clinical trials for t1xbet 로그인 agitation indication that were completed by Otsuka and Lundbeck earlier this year. Top-line results for t1xbet 로그인 two completed trials were announced in May 2017.
Latest Pharmaceutical Business related News Releases